v3.26.1
Consolidated Statements of CashFlows - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Cash Flows From Operating Activities:    
Net loss $ (24,952,378) $ (9,413,435)
Adjustments to reconcile net loss to net cash used in operating activities:    
Impairment of in-process research and development 18,647,903
Stock-based compensation 222,831 705,567
Issuance of common stock pursuant to vendor agreements 240,000 196,770
Write-off of deferred offering costs 57,238
Depreciation of fixed assets 6,933
Non-cash rent expense 7,839
Deferred tax (benefit) provision (851,659) 6,745
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (46,766) 30,586
Accounts payable 689,268 888,609
Vendor deposits 161,927 (80,000)
Operating lease liability (8,656)
Accrued expenses and other current liabilities 717,255 139,508
Net Cash Used In Operating Activities (5,114,381) (7,519,534)
Cash Flows From Financing Activities:    
Exercise of warrants 2,672,500
Private placement of warrants 1,999,791
Warrant inducement offer - exercise proceeds 2,051,852 2,514,088
Exercise of pre-funded warrants 210
Payment of offering costs (40,163)
At the market issuance of stock proceeds 1,354,404
Registration and issuance costs associated with warrant issuance (366,618) (588,045)
Net Cash Provided By Financing Activities 3,685,235 5,912,784
Net Decrease in Cash (1,429,146) (1,606,750)
Cash - Beginning of Period 1,530,924 3,137,674
Cash - End of Period 101,778 1,530,924
Supplemental Disclosures of Cash Flow Information:    
Interest
Income taxes
Non-cash investing and financing activities:    
Warrant modifications - incremental value 1,816,646 3,033,284
Accounts payable and accrued expenses for offering costs $ 98,921 $ 17,075